G2A is expressed mainly in immune cells including T and B-lymphocytes, monocytes, macrophages and dendritic cells. Currently, G2A and its related GPCRs are implicated in a variety of diseases including autoimmune disorders, inflammation and cancer. However the exact biological functions of these GPCRs have not been elucidated. Therefore, readily available research tools such as those generated by the UCLA investigators could significantly accelerate the research to better understand the role of these GPCRs under physiological and pathological conditions.

INNOVATION:  Researchers at UCLA identified, characterized and patented the G2A GPCR. To help in the elucidation of the biological functions of G2A, these researchers have also developed a G2A GPCR deficient mouse model along with polyclonal and monoclonal antibodies useful for immunoprecipitations and Western blots. These tools may be used to study G2A to better understand its function in a variety of disorders and to also develop therapeutics that target this GPCR.

ADVANTAGES

• Novel GPCR may be targeted to develop therapies that treat a variety of disorders
• Readily available G2A deficient mouse model that can be used to study G2A and used as a screen for novel therapies that involve G2A dysfunction
• Readily available G2A antibodies may be used for immunoprecipitations and Western blots to screen for G2A expression
• G2A may be used as a diagnostic

Reference: UCLA Case No. 1997-538

US Patent Numbers: 6,709,830 | 6,569,995 6,514,696 | 6,383,760 6,214,562 | 6,207,412